AZN: H1 2021 Results
AstraZeneca PLC29 July 2021 07:00 BST H1 2021 resultsAccelerating top-line growth with continued pipeline progressunderpins the transition to long-term sustainable growth AstraZeneca delivered strong revenue growth of 23% (18% at CER[1]) in the half to $15,540m while, in the second quarter, revenue increased by 31% (25% at CER) to $8,220m. Excluding the contribution from the pandemic COVID-19 vaccine, revenue increased by 14% (9% at CER) in the half to $14,371m and by 17% (12% at CER) in the quarter to $7,326m. Further pipeline progress and the recent acquisition of Alexion